18,287 Shares in Xencor, Inc. (NASDAQ:XNCR) Bought by Intech Investment Management LLC

Intech Investment Management LLC acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 18,287 shares of the biopharmaceutical company’s stock, valued at approximately $368,000.

Other hedge funds have also bought and sold shares of the company. Panagora Asset Management Inc. raised its position in shares of Xencor by 9.4% in the second quarter. Panagora Asset Management Inc. now owns 232,375 shares of the biopharmaceutical company’s stock valued at $4,399,000 after purchasing an additional 20,043 shares during the period. Primecap Management Co. CA grew its stake in Xencor by 0.3% in the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after buying an additional 25,495 shares during the last quarter. AQR Capital Management LLC bought a new position in Xencor in the 2nd quarter valued at about $753,000. Dimensional Fund Advisors LP lifted its position in Xencor by 6.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock worth $27,628,000 after acquiring an additional 87,979 shares during the last quarter. Finally, Essex LLC bought a new stake in shares of Xencor during the third quarter worth approximately $2,668,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on XNCR. Wedbush reiterated an “outperform” rating and issued a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $20.00 to $30.00 in a report on Monday. BMO Capital Markets restated an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. Royal Bank of Canada increased their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $36.50.

Xencor Trading Down 0.9 %

Shares of XNCR stock opened at $26.60 on Wednesday. Xencor, Inc. has a twelve month low of $15.31 and a twelve month high of $27.20. The stock’s fifty day simple moving average is $22.19 and its 200 day simple moving average is $20.56. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.86 billion, a P/E ratio of -8.31 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business’s quarterly revenue was down 81.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.40) earnings per share. As a group, sell-side analysts predict that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

Insider Buying and Selling at Xencor

In related news, VP John R. Desjarlais sold 68,684 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bassil I. Dahiyat sold 3,366 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total transaction of $80,851.32. Following the completion of the transaction, the chief executive officer now owns 352,615 shares in the company, valued at $8,469,812.30. This trade represents a 0.95 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 121,328 shares of company stock worth $2,879,673. 5.23% of the stock is currently owned by company insiders.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.